H.C. Wainwright Maintains Medicenna Therapeutics(MDNAF.US) With Buy Rating, Maintains Target Price $2.5
Bloom Burton Maintains Medicenna Therapeutics(MDNAF.US) With Buy Rating, Maintains Target Price $6
Medicenna Therapeutics Corp (MDNA) Gets a Buy Rating From Bloom Burton
Medicenna Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Target
Medicenna Therapeutics Analyst Ratings
Medicenna Therapeutics Corp (MDNA) Gets a Buy Rating From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Target
Medicenna Therapeutics Analyst Ratings
H.C. Wainwright Maintains Their Buy Rating on Medicenna Therapeutics Corp (MDNA)
HC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Target
Watching Medicenna Therapeutics; Zacks Small-Cap Research Sets $7/Price Target
Medicenna Therapeutics Analyst Ratings
Guggenheim Initiates Coverage On Medicenna Therapeutics With Buy Rating, Announces Price Target of C$2
HC Wainwright Adjusts Price Target on Medicenna Therapeutics to $2.50 From $4, Maintains Buy Rating
Medicenna Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $2.5
Medicenna Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4
Oppenheimer Adjusts Medicenna Therapeutics Price Target to $8 From $10, Maintains Outperform Rating